Amitriptyline Versus Amitriptyline Combined With Fluoxetine in the Preventative Treatment of Transformed Migraine: A Double‐Blind Study

Krymchantowski, Abouch Valenty; Silva, Marcus Tulius T.; Barbosa, Jackeline Soraya; Alves, Luiz Anastácio

doi:10.1046/j.1526-4610.2002.02125.x

Cited by 70 publications

(66 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A doubleblind placebo-controlled study showed fluoxetine to be useful in the treatment of chronic daily head a c h e 1 1 . Others, using it in association with amitriptyline, could not observe this effect 12 . The objective of this study was to test the eff icacy of fluoxetine prophylaxis in a group of child ren and adolescents with primary CDH thro u g h a prospective, randomized, double blind, placebo-controlled, crossover study.…”

mentioning

confidence: 95%

A prospective randomized double blind placebo controlled crossover study of fluoxetine efficacy in the prophylaxis of chronic daily headache in children and adolescents

Gherpelli

Esposito

2005

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

-Thirty-two children (21 female and 11 male), between 7 and 14 years old, with chronic daily headache (CDH) were consecutively included in a prospective, randomized, double blind, placebo cont rolled crossover study. The patients were divided in group I (fluoxetine vs. placebo), with 17 patients and g roup II (placebo vs. fluoxetine), with 15 patients. After one month of baseline headache frequency re c o rding, the patients received fluoxetine in dosages from 0.25 to 0.50 mg/kg for three months. A wash out period of one month was followed by another three months treatment period. Results showed a significant decrease in headache frequency in the study period [78% reduction in group I (p<0.025), and 45% reduction in group II (p=0.025)]. Gastrointestinal adverse effects were observed in nine patients (29%) that received fluoxetine, compared with 3 (10%), with placebo. We conclude that fluoxetine efficacy is not higher than placebo in the prophylaxis of CDH in children and adolescents.KEY WORDS: headache, chronic daily headache, children and adolescents, migraine, fluoxetine.Estudo randomizado prospectivo duplo-cego cruzado controlado com placebo da eficácia da fluoxetina na profilaxia da cefaléia crônica diária na infância e adolescência RESUMO -Trinta e duas crianças (21 feminino, 11 masculino), com idades entre 7 e 14 anos, com cefaléia crônica diária (CCD) foram incluídos consecutivamente no estudo prospectivo, randomizado, duplo-cego, c ruzado com placebo. Os pacientes foram divididos em grupo I (fluoxetina vs. placebo), com 17 pacientes, e grupo II (placebo vs. fluoxetina) , com 15 pacientes. Após um mês de registro da freqüência da cefaléia, os pacientes receberam fluoxetina em doses de 0,25-0,5 mg/kg por três meses. Após período de interru p ç ã o da droga de um mês, seguiu-se novo período de três meses de tratamento. Os resultados mostraram diminuição estatisticamente significativa da freqüência da cefaléia [78% de redução no grupo I (p<0,025) e 45% de redução no grupo II (p<0,025)]. Efeitos colaterais gastrointestinais ocorreram em 9 pacientes (29%) na vigência da fluoxetina, comparado com 3 (10%) com placebo. Concluímos que não houve diferença entre o efeito da fluoxetina e do placebo na profilaxia da CCD em crianças e adolescentes.

show abstract

mentioning

confidence: 95%

A prospective randomized double blind placebo controlled crossover study of fluoxetine efficacy in the prophylaxis of chronic daily headache in children and adolescents

Gherpelli

Esposito

2005

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…12 Evidence-based prophylactic medications for episodic migraine are often used for chronic migraine. These agents include topiramate, 13,14 gabapentin, 15 tizanidine, 16 fluoxetine, 17 amitriptyline, 18 and valproate. 19,20 It is important to note that of these agents commonly used for treating episodic migraine, only topiramate has been shown to be efficacious in randomized, placebo-controlled clinical trials in patients with chronic migraine.…”

Section: Treatment Plan For Chronic Migrainementioning

confidence: 99%

Best Practices for Patients With Chronic Migraine

Starling

Dodick

2015

Mayo Clinic Proceedings

View full text Add to dashboard Cite

Headache and migraine are common medical complaints among patients visiting primary care physicians (PCPs). A number of these patients may have chronic migraine, which is more difficult to diagnose and manage than many other headache disorders. Identification of those at risk, correct diagnosis, and establishment of a comprehensive management plan for patients with chronic migraine will require a joint effort between the PCP and the headache specialist. Together, the PCP and headache specialist will need to assess the patient for modifiable exacerbating factors and comorbidities while managing prophylactic and as-needed therapies. Herein, we provide a review of chronic migraine for the PCP and describe tools for improving patient care.

show abstract

“…15 One randomized open study in 49 subjects with CM compared sodium valproate 750 mg/day to topiramate 75 mg/day. 16 Three months after randomization, significant reduction in 30-day headache days with respect to baseline ( p Ͻ 0.00001) and significant reduction in Migraine Disability Assessment (MIDAS) scores ( p Ͻ 0.00001) were recorded in both groups.…”

Section: Treatment Options For Chronic Migrainementioning

confidence: 99%